Paper · 19615940
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME and 15 others. Lancet Oncol, 2009. Cited by 487 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Papers, record 19615940. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19615940
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Renal Cell | Major topic |
| Indoles | Major topic |
| Kidney Neoplasms | Major topic |
| Pyrroles | Major topic |
| Disease-Free Survival | |
| Humans | |
| Sunitinib | |
| Survival Analysis |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00130897 | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 19,615,941 | Sunitinib in renal-cell carcinoma: expanded indications. | https://conductscience.org/library/papers/19615941 | PubMed |
| Comment in | 19,942,921 | Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit? | https://conductscience.org/library/papers/19942921 | PubMed |
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by215
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 487 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,836,013 | Epithelial-mesenchymal transition and sunitinib resistance in renal cell carcinoma: mechanisms and therapeutic strategies. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41836013 | PubMed |
| 41,517,566 | The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib. | J Clin Med | 2026 | https://conductscience.org/library/papers/41517566 | PubMed |
| 40,944,871 | Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives. | Cancer Chemother Pharmacol | 2025 | https://conductscience.org/library/papers/40944871 | PubMed |
| 40,698,025 | The Influence of Safety Performance on Competitive Advantage in the Shipping Industry: A Systematic Literature Review Study. | F1000Res | 2025 | https://conductscience.org/library/papers/40698025 | PubMed |
| 40,284,020 | Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40284020 | PubMed |
| 39,743,997 | Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis. | Front Oncol | 2024 | https://conductscience.org/library/papers/39743997 | PubMed |
| 39,543,725 | Transcriptome-based network analysis related to regulatory T cells infiltration identified RCN1 as a potential biomarker for prognosis in clear cell renal cell carcinoma. | BioData Min | 2024 | https://conductscience.org/library/papers/39543725 | PubMed |
| 39,250,424 | Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. | Health Technol Assess | 2024 | https://conductscience.org/library/papers/39250424 | PubMed |
| 38,622,715 | Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification. | Eur J Med Res | 2024 | https://conductscience.org/library/papers/38622715 | PubMed |
| 38,618,396 | Nephrotic Syndrome Due to Sunitinib: A Rare Complication of Treatment of Renal Cell Carcinoma. | Cureus | 2024 | https://conductscience.org/library/papers/38618396 | PubMed |
1 to 10 of 215
See all 215 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| SUNITINIB | CHEMBL535 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL535 |
Source ChEMBL
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19615940
GET https://conductscience.org/api/papers/v1/19615940/cited_by?page=2